The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Fast Track, 2002Testosterone Therapy in Parkinson's disease
The University of Florida Movement Disorders Center will be following up the promising results of two preliminary studies of testosterone replacement therapy in male Parkinson's disease patients in a...
-
Fast Track, 2002Signaling Cascades Underlying Use-dependent Neuroprotection in Parkinsonism
Parkinson's disease is characterized by the progressive loss of nerves in the brain that produce a chemical called dopamine, which is important in the control of motor function. Current therapies...
-
Fast Track, 2002Differentiation catalysts for the production of dopaminergic neurons
Embryonic stem (ES) cells can replicate indefinitely in an undifferentiated state and develop into all cells and tissues in the body. These unique characters of ES cells imply their application as a...
-
Fast Track, 2002Pre-clinical Model for Pharmacological Upregulation of Molecular Chaperones
Lewy bodies including alpha-synuclein in substantia nigra neurons are characteristic of Parkinson's disease. These aggregates may cause the disease or may represent disease-causing protein folding...
-
Fast Track, 2002The role of the DJ-1 gene in early-onset recessive Parkinson's Disease (PARK7)
Several families with rare genetic forms of Parkinson's disease have been identified, and at present mutations in three genes implicated in familial forms of parkinsonism have been described: the...
-
Cell Line, 2002Development of a Stem Cell Replacement Therapy for Parkinson's Disease: Induction of Midbrain DA Neurons from ES Cells
In the present project three groups at the Karolinska Institute join forces in order to: 1) Identify molecular players capable of inducing a midbrain dopaminergic (DA) phenotype. We previously found...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.